Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis

Eligibility Criteria

• 1. Male or female \> 18 years of age.
• 2. X ray diagnosis of CMC osteoarthritis Eaton stages I, II or III.
• 3. VAS pain score in affected thumb of 5 or greater.
• 4. Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
• 5. Willing to abstain from use of the following protocol-restricted medications during the study to be kept in a log if non compliant.
• * Opioid or over the counter medications for pain for the study duration
• 1. Females who are pregnant or nursing or plan to become pregnant during the study; women who plan to conceive during the study; or unwilling to practice birth control during participation in the study.
• 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
• 3. Known or suspected hypersensitivity to TA-ER (or component of TA-ER), triamcinolone acetonide.
• 4. Stage IV CMC osteoarthritis is excluded. Rationale for exclusion of stage IV is that these patients are most likely surgical candidates due to severe joint damage. Other exclusion criteria include rheumatoid arthritis, septic or gouty arthritis or psoriatic arthritis, thumb joint effusion, DeQuervain's disease, trigger thumb or history of CMC joint surgical reconstruction, or terminal or chronic and serious, uncontrolled associated medical conditions. Patients who have received hyaluronan or platelet rich plasma (PRP) injections to the affected CMC joint within 6 months will be excluded. Patients who have received a steroid injection to the affected CMC joint within 3 months will be excluded.